GlassScriptPhysician profile
Jesse E Medellin
NPI 1770506297
$2,385.95
in general payments reported to CMS, 2019-2025
35 companies · $94.57 in 2025
The $94.57 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,476 · 2020: $266 · 2021: $96.17 · 2022: $256 · 2023: $50.22 · 2024: $148 · 2025: $94.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $256 · Education: $36.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $256.26 |
| Education | $36.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $319.32 | 2019-2025 | |
| Janssen Biotech, INC. | $290.02 | 2019-2022 | |
| Incyte Corporation | $247.20 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $201.87 | 2019-2025 | |
| Amgen INC. | $185.54 | 2019-2025 | Vectibix |
| Exelixis INC. | $129.53 | 2019 | |
| Merck Sharp & Dohme LLC | $108.55 | 2019-2023 | Lynparza |
| Astrazeneca Pharmaceuticals LP | $91.69 | 2019-2022 | |
| Astellas Pharma US INC | $72.89 | 2019-2020 | |
| Pfizer INC. | $69.33 | 2019-2021 | |
| Genzyme Corporation | $66.33 | 2019-2022 | |
| Celgene Corporation | $59.34 | 2019-2025 | Reblozyl |
| Puma Biotechnology, INC. | $54.57 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.74 | 2019 | |
| Lilly USA, LLC | $50.93 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $37.67 | 2019-2020 | |
| Gilead Sciences, INC. | $33.34 | 2021 | |
| Seagen INC. | $28.43 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $26.44 | 2019 | |
| Blueprint Medicines Corporation | $21.79 | 2024 | Ayvakit |
| Medtronic USA, INC. | $19.92 | 2019 | |
| Agios Pharmaceuticals, INC. | $19.47 | 2024 | Pyrukynd |
| Daiichi Sankyo INC. | $18.50 | 2020 | |
| Genentech USA, INC. | $17.99 | 2019 | |
| Abbvie INC. | $17.62 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Emd Serono, INC. | $16.72 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.40 | 2019 | |
| Biocompatibles, INC. | $15.14 | 2019 | |
| Dova Pharmaceuticals | $14.48 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $14.26 | 2020 | |
| Amag Pharmaceuticals, INC. | $14.22 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.77 | 2019 | |
| Rigel Pharmaceuticals, INC. | $12.10 | 2022 | |
| Eisai INC. | $11.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Medellin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.